DexCom, Inc. (NASDAQ:DXCM) today announced that The Greater Los Angeles Chapter of the Juvenile Diabetes Research Foundation (JDRF) will bestow one of its highest honors, the 2010 Angel Award, to Terry and Louise Gregg. The Greggs have long been active supporters and personal contributors to diabetes research. The Greggs will receive the award at the JDRF's annual fundraiser gala on May 6, 2010 at the Beverly Hilton Hotel. Past honorees include First Lady Nancy Reagan, award winning singer/songwriter Garth Brooks, champion boxer Sugar Ray Leonard, pediatric endocrinologist Francine Kaufman, and philanthropist Barbara Davis.
"The leadership, passion and commitment that Terry and Louise have shown in the fight against diabetes have been uniquely incredible. They have made a real impact that few others have done," said Steve Edelman, Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California, San Diego and founder and director of Taking Control of Your Diabetes. "Louise and I are honored by this recognition and we will continue to work with those that are motivated to making a difference in the diabetes world until a cure is found," said Gregg.
Terrance H. Gregg is President and CEO of DexCom, Inc. He is also currently a Special Venture Partner with Galen Partners, a private equity firm specializing in the healthcare industry. Additionally Mr. Gregg sits on the board of directors of "Taking Control of Your Diabetes," a non-profit educational program. In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic's $3.4 billion acquisition of MiniMed in 2001. Mr. Gregg served as the 2003-2004 Chair of the Research Foundation Board of the American Diabetes Association, and in 2003, Mr. Gregg and his wife were recognized by the American Diabetes Association with an award for Outstanding Service in Diabetes Research Funding.
Since its founding in 1970 by parents of children with Type 1 diabetes, JDRF has awarded more than $1.3 billion to diabetes research grants. The Los Angeles Chapter contributes roughly $4 million annually to diabetes research.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company's products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company's inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's annual report on Form 10-K for the period ending December 31, 2009, as filed with the Securities and Exchange Commission on March 9, 2010.
Contacts:
DexCom, Inc.
Steven R. Pacelli, Chief Administrative Officer
858-200-0200